Suberoylanilide Hydroxamic Acid as a Potential Therapeutic Agent for Human Breast Cancer Treatment

[1] Hortobagyi GN(1998)Drug therapy—treatment of breast cancer N. Engl. J. Med. 339 974-984

[2] Holdener EE(1993)Retinoids Curr. Opin. Oncol. 5 1059-1066

[3] Bollag W(1998)Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer Clin. Cancer Res. 4 635-642

[4] Budd GT(1996)Second generation hybrid polar compounds are potent inducers of transformed cell differentiation Proc. Natl. Acad. Sci. U.S.A. 93 5705-5708

[5] Adamson PC(1997)Two cytodifferentiation agent-induced pathways, differentiation and apoptosis, are distinguished by the expression of human papillomavirus 16 E7 in human bladder carcinoma cells Cancer Res. 57 2789-2798

[6] Gupta M(1998)Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells Proc. Natl. Acad. Sci. U.S.A. 95 162-166

[7] Richon VM(1992)Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent Blood 80 2604-2609

[8] Webb Y(1999)Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53 Oncogene 18 7016-7025

[9] Merger R(1999)Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA) Anticancer Res. 19 4999-5005

[10] Richon VM(1999)Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiating agent, suberanilohydroxamic acid (SAHA) Anticancer Res. 19 4999-5005

[1] Hortobagyi GN(1998)Drug therapy—treatment of breast cancer N. Engl. J. Med. 339 974-984

[2] Holdener EE(1993)Retinoids Curr. Opin. Oncol. 5 1059-1066

[3] Bollag W(1998)Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer Clin. Cancer Res. 4 635-642

[4] Budd GT(1996)Second generation hybrid polar compounds are potent inducers of transformed cell differentiation Proc. Natl. Acad. Sci. U.S.A. 93 5705-5708

[5] Adamson PC(1997)Two cytodifferentiation agent-induced pathways, differentiation and apoptosis, are distinguished by the expression of human papillomavirus 16 E7 in human bladder carcinoma cells Cancer Res. 57 2789-2798

[6] Gupta M(1998)Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells Proc. Natl. Acad. Sci. U.S.A. 95 162-166

[7] Richon VM(1992)Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent Blood 80 2604-2609

[8] Webb Y(1999)Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53 Oncogene 18 7016-7025

[9] Merger R(1999)Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA) Anticancer Res. 19 4999-5005

[10] Richon VM(1999)Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiating agent, suberanilohydroxamic acid (SAHA) Anticancer Res. 19 4999-5005